Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | SPR | P35270 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3722326 | 0.78 | USP2 (0.47) | USP2SMN1; SMN2 | |
| SCHEMBL27374605 | 0.75 | JAK3 (0.43) | JAK3USP2SMN1; SMN2CNR2CNR1 | |
| SCHEMBL4439843 | 0.73 | USP2 (0.40) | USP2SMN1; SMN2CNR2 | |
| SCHEMBL22047121 | 0.71 | CHRM2 (0.35) | USP2SMN1; SMN2GRIN2BGRIN2C | |
| SCHEMBL31078106 | 0.70 | HSD17B10 (0.39) | USP2SMN1; SMN2 | |
| SCHEMBL2981422 | 0.69 | JAK3 (0.48) | JAK3USP2SMN1; SMN2GRIN2BGRIN2C | |
| SCHEMBL14669188 | 0.69 | JAK3 (0.45) | JAK3USP2SMN1; SMN2CNR2CNR1 | |
| SCHEMBL29348856 | 0.68 | USP2 (0.45) | JAK3USP2SMN1; SMN2CNR2CNR1 | |
| SCHEMBL29584537 | 0.68 | JAK3 (0.47) | JAK3USP2SMN1; SMN2CNR2CNR1 | |
| SCHEMBL8418642 | 0.68 | JAK3 (0.49) | JAK3USP2SMN1; SMN2CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111251-A1 | COMPOUNDS THAT INHIBIT POLO-LIKE KINASE 4 | EXELIXIS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |